Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial

PLIANT THERAPEUTICS, INC.

2026-Q1 EPS reported -$0.32

Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.
Cash, equivalents and short-term investments $172.4M; expected to fund operations into H2 2028.
First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027.
Updated Phase 1 data at AACR showed deepening responses: one complete response, two partial responses in checkpoint-refractory tumors.
Integrin-targeted delivery platform advancing for siRNA delivery to skeletal muscle; preclinical proof-of-concept ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: net income Net loss was $20.0 million.

Period: first quarter ended March 31, 2026
Net income: Net loss was $20.0 million
Result: reported results

Exact text from the filing

On May 11, 2026, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-26-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.